The answer to is MOTS-c FDA approved is still no. There is no approved MOTS-c medicine in the United States. July's vote favored adding ingredients to a compounding list for pharmacies preparing medicines for individual prescriptions. It wasn't a decision clearing a finished drug.
MOTS-c prescribed through Promise is dispensed by a licensed U.S. compounding pharmacy as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. A licensed provider may still prescribe — that decision is between you and your doctor.
How the MOTS-c FDA nomination began
MOTS-c is a peptide, a short chain of protein building blocks. Wells Pharmacy Network submitted the nomination in docket FDA-2015-N-3534. The original docket record says FDA received it March 24, 2021, and posted it April 1.
A nomination is a request to consider a raw medicine ingredient. The 503A bulks list is FDA's ingredient list for compounding under the federal framework for prescriptions prepared for individual patients.
The proposal described 5 mg and 10 mg injectable preparations given under the skin. Its proposed uses included insulin resistance, meaning a weaker response to the hormone controlling blood sugar, and obesity, or excess body fat. Other proposed uses were osteoporosis, or fragile bones, and vascular calcification, or calcium buildup in blood vessels. The list also included how muscle and fat handle fuel, and longer lifespan. FDA's July presentation records these as proposed uses, without evidence from studies in people supporting them.
Category 2, then a withdrawn nomination
FDA's archived safety table dates MOTS-c's placement in 503A Category 2 to September 29, 2023. That category identifies ingredients with significant safety concerns. Our Category 2 explainer covers the wider system.
On April 14, 2026, Wells withdrew 12 nominations. MOTS-c appears as item nine in the withdrawal record.
FDA's current nominations PDF carries the stamp “Updated May 14, 2026.” MOTS-c no longer appears in its active categories. The current safety page places it among withdrawn nominations and retains its safety concerns.
Withdrawal took back the request; it did not establish the ingredient's safety. For someone weighing a prescription, that paperwork change doesn't choose a treatment or settle the evidence behind it.
What FDA staff found in the May 11 review
The briefing memo dated May 11, 2026 explains that FDA continued evaluating MOTS-c on its own initiative after withdrawal.
The nomination left the ingredient's identity unclear. Some identifiers pointed to the free base, the form without an added salt. Its testing certificate concerned acetate, a salt form. FDA reviewed both.
Staff found missing information about unwanted material, peptide clumps and bacterial contamination. Those gaps matter because they can affect quality and immunogenicity, meaning an immune reaction to the preparation.
Reviewers also found no public studies showing what happened when people received either ingredient. Human data on how administered MOTS-c moves through the body were missing, too. Staff recommended against adding either form to the list.
The distinction between measuring MOTS-c and giving it to someone helps explain that gap. The 2015 Cell Metabolism paper studied treatment effects in mice; our discovery history follows its origins. In the 2021 Nature Communications exercise study, researchers measured the MOTS-c made by 10 men during cycling. They did not give those men the peptide.
July 23: the committee favored inclusion
The Pharmacy Compounding Advisory Committee, or PCAC, is an outside panel that advises FDA. On July 23, 2026, it considered the two MOTS-c ingredients separately.
The official FDA recording shows the free-base tally. Later, the panel voted on MOTS-c acetate, with the same result:
| Ingredient | In favor | Against | Abstained |
|---|---|---|---|
| MOTS-c free base | 7 | 5 | 2 |
| MOTS-c acetate | 7 | 5 | 2 |
FDA has posted no minutes or transcript, so the individual votes are not summarized here.
Each vote recommended adding an ingredient to the 503A bulks list. FDA's meeting page explains that these recommendations are nonbinding. The whole-meeting account covers the other peptides considered alongside MOTS-c.
What happened after the vote
As of October 1, 2026, the day this article was written, no proposed or final MOTS-c rule has followed July's recommendation. FDA's ingredient overview, still marked “Content current as of: 05/14/2026,” describes the existing list and the rulemaking process.
On October 28, 2026, HHS filed its draft peptide enforcement policy for Federal Register publication on October 30; Appendix A names MOTS-c, and Appendix B specifies MOTS-c acetate for subcutaneous or intramuscular injectable dosage forms. The policy is nonbinding, not FDA approval, and separate from final 503A bulks-list rulemaking still to come.
Rulemaking means writing a regulation through a public process. A proposal, public comments and a final regulation are separate steps from a committee vote. The staff recommendation in a briefing memo is also a different document from a proposed regulation.
FDA's next PCAC meeting page says a meeting will occur before the end of February 2027. Its five-substance agenda does not include MOTS-c. That meeting announcement supplies no deadline for a MOTS-c rule. Our September MOTS-c update keeps the quarter's developments together.
What the human trial adds to this record
As of October 1, 2026, the day this article was written, the MOTS-MET registry lists Hudson Biotech's study as recruiting. This early treatment study plans to enroll 120 people. It is the only ClinicalTrials.gov-registered trial we found that gives MOTS-c itself to people. Its record was last updated April 1, 2026, and has no posted results.
That number is the study's target, rather than a count of people already treated. The record lists a site in China and marks the study as not involving a U.S. FDA-regulated drug. A registry entry describes a study; it doesn't establish benefit or put a drug under FDA review.
As of October 1, 2026, the day this article was written, newer laboratory findings also leave that treatment question open. An eLife paper published August 18, 2026 examined MOTS-c in immune defense using bacteria, cultured cells and mice. Human cells in a laboratory are different from patients receiving treatment.
Is MOTS-c FDA approved? Still not
The nomination, withdrawal and favorable vote have not produced an approved MOTS-c medicine. They also haven't established a human dose, long-term safety or a result for the compounded formulation offered here.
As of October 1, 2026, the day this article was written, the 2027 list from WADA, the World Anti-Doping Agency, names MOTS-c under S4.4.1 as prohibited at all times; published September 21, that edition takes effect January 1, 2027 (sport-rules explainer).
For a prescribing conversation, the useful questions concern the exact formulation, the treatment goal, other medicines and how follow-up would work. A list position cannot answer those questions for a particular person.
At Promise, a licensed provider reviews every request, and not everyone qualifies. If a prescription is written, the provider sets the actual dose and monitoring plan. That conversation remains about the person and the preparation, alongside what the public record does and doesn't establish.
